The Direct Economic Cost of Pharmacologically-Treated Diabetes in Italy-2006. The ARNO Observatory

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 21, Issue 5, 2011, Pages 339-346

  Marchesini, G ^a   Forlani, G ^a   Rossi, E ^b   Berti, A ^b   De Rosa, M ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b CINECA   (Italy)

Author keywords

Diabetes cost; Diabetes prevalence; Glucose lowering drugs; Hospital admission; Non glucose lowering drugs; Service use

Indexed keywords

ANTIDIABETIC AGENT; INSULIN;

ARTICLE; CAUCASIAN; DRUG COST; ECONOMICS; HOSPITAL COST; HOSPITALIZATION; HUMAN; INCIDENCE; ITALY; LONGITUDINAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; STATISTICS;

DIABETES MELLITUS, TYPE 2; DRUG COSTS; EUROPEAN CONTINENTAL ANCESTRY GROUP; HOSPITAL COSTS; HOSPITALIZATION; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; INSULIN; ITALY; LONGITUDINAL STUDIES; PREVALENCE;

EID: 79954630138     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2009.10.009     Document Type: Article

References (27)

1. American Diabetes Association Economic costs of diabetes in the U.S. in 2007. Diabetes Care 2008, 31:596-615.
2. Gulliford M.C., Latinovic R., Charlton J. Diabetes diagnosis, resource utilization, and health outcomes. The American Journal of Managed Care 2008, 14:32-38.
3. Bruno G., Karaghiosoff L., Merletti F., Costa G., De Maria M., Panero F., et al. The impact of diabetes on prescription drug costs: the population-based Turin study. Diabetologia 2008, 51:795-801.
4. Lucioni C., Garancini M.P., Massi-Benedetti M., Mazzi S., Serra G. CODE-2 Italian Advisory Board. The costs of type 2 diabetes mellitus in Italy: a CODE-2 sub-study. Treatments in Endocrinology 2003, 2:121-133.
5. Sullivan P.W., Ghushchyan V., Wyatt H.R., Hill J.O. The medical cost of cardiometabolic risk factor clusters in the United States. Obesity 2007, 15:3150-3158.
6. Bottomley J.M., Raymond F.D. Pharmaco-economic issues for diabetes therapy. Best Practice & Research 2007, 21:657-685.
7. Henriksson F., Agardh C.D., Berne C., Bolinder J., Lonnqvist F., Stenstrom P., et al. Direct medical costs for patients with type 2 diabetes in Sweden. Journal of Internal Medicine 2000, 248:387-396.
8. Jonsson B., CODE-2 Advisory Board Revealing the cost of Type II diabetes in Europe. Diabetologia 2002, 45:S5-12.
9. Koster I., von Ferber L., Ihle P., Schubert I., Hauner H. The cost burden of diabetes mellitus: the evidence from Germany-the CoDiM study. Diabetologia 2006, 49:1498-1504.
10. Liebl A. International Journal of Dermatology 2007, 48:708-714.
11. Schwarz P.E., Lindstrom J., Kissimova-Scarbeck K., Szybinski Z., Barengo N.C., Peltonen M., et al. The European perspective of type 2 diabetes prevention: diabetes in Europe - prevention using lifestyle, physical activity and nutritional intervention (DE-PLAN) project. Experimental and Clinical Endocrinology and Diabetes 2008, 116:167-172.
12. Soljak M.A., Majeed A., Eliahoo J., Dornhorst A. Ethnic inequalities in the treatment and outcome of diabetes in three English Primary Care Trusts. International Journal for Equity in Health 2007, 6:8.
13. Stock S.A., Redaelli M., Wendland G., Civello D., Lauterbach K.W. Diabetes-prevalence and cost of illness in Germany: a study evaluating data from the statutory health insurance in Germany. Diabetic Medicine 2006, 23:299-305.
14. Wallemacq C., Van Gaal L.F., Scheen A.J. Revue Medicale de Liege 2005, 60:278-284.
15. Dawson K.G., Gomes D., Gerstein H., Blanchard J.F., Kahler K.H. The economic cost of diabetes in Canada, 1998. Diabetes Care 2002, 25:1303-1307.
16. Orszag P.R., Ellis P. Addressing rising health care costs-a view from the congressional budget office. The New England Journal of Medicine 2007, 357:1885-1887.
17. Weinstock R.S., Hawley G., Repke D., Feuerstein B.L., Sawin C.T., Pogach L.M. Pharmacy costs and glycemic control in the department of veterans affairs. Diabetes Care 2004, 27(Suppl. 2):B74-81.
18. Davis W.A., Knuiman M.W., Hendrie D., Davis T.M. The obesity-driven rising costs of type 2 diabetes in Australia: projections from the Fremantle Diabetes Study. Internal Medicine Journal 2006, 36:155-161.
19. Kapur A. Economic analysis of diabetes care. The Indian Journal of Medical Research 2007, 125:473-482.
20. Oishi M., Yokoyama H., Abe N., Iwasaki K., Okuguchi F., Kawai K., et al. Time and cost involved in the care of newly registered patients with diabetes mellitus and other lifestyle diseases at diabetes clinics in Japan (JDDM 4). Diabetic Medicine 2007, 24:1149-1155.
21. Cowie C.C., Rust K.F., Byrd-Holt D.D., Eberhardt M.S., Flegal K.M., Engelgau M.M., et al. Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: national health and nutrition examination survey 1999-2002. Diabetes Care 2006, 29:1263-1268.
22. Narayan K.M., Boyle J.P., Geiss L.S., Saaddine J.B., Thompson T.J. Impact of recent increase in incidence on future diabetes burden: U.S., 2005-2050. Diabetes Care 2006, 29:2114-2116.
23. Brown D.A., Unrein C. A review of cardiovascular comorbidities in diabetes. American Journal of Managed Care 2007, 13:3-10.
24. Adeyi O., Smith O., Robles S. Public policy and the challenge of chronic noncommunicable diseases 2007, The World Bank, Washington, D.C.
25. Goetzel R.Z., Hawkins K., Ozminkowski R.J., Wang S. The health and productivity cost burden of the " top 10" physical and mental health conditions affecting six large U.S. employers in 1999. Journal of Occupational and Environmental Medicine 2003, 45:5-14.
26. The Economist Intelligence Unit. The silent epidemics. An economic study of diabetes in developed and developing countries. London; 2007.
27. Goetzel R.Z., Ozminkowski R.J., Villagra V.G., Duffy J. Return on investment in disease management: a review. Health Care Financial Review 2005, 26:1-19.